Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review
- PMID: 25489265
- PMCID: PMC4257121
- DOI: 10.3747/co.21.2125
Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review
Abstract
Background: Combined positron-emission tomography and computed tomography (pet-ct) reduces futile thoracotomy (ft) rates in patients with non-small-cell lung cancer (nsclc). We sought to identify preoperative risk factors for ft in patients staged with pet-ct.
Methods: We retrospectively reviewed all patients referred to the BC Cancer Agency during 2009-2010 who underwent pet-ct and thoracotomy for nsclc. Patients with clinical N2 disease were excluded. An ft was defined as any of a benign lesion; an exploratory thoracotomy; pathologic N2 or N3, stage iiib or iv, or inoperable T3 or T4 disease; and recurrence or death within 1 year of surgery.
Results: Of the 108 patients who met the inclusion criteria, ft occurred in 27. The main reason for ft was recurrence within 1 year (14 patients) and pathologic N2 disease (10 patients). On multivariate analysis, an Eastern Cooperative Oncology Group performance status greater than 1, a pet-ct positive N1 status, a primary tumour larger than 3 cm, and a period of more than 16 weeks from pet-ct to surgery were associated with ft. N2 disease that had been negative on pet-ct occurred in 21% of patients with a pet-ct positive N1 status and in 20% of patients with tumours larger than 3 cm and non-biopsy mediastinal staging only. The combination of pet-ct positive N1 status and a primary larger than 3 cm had 85% specificity, and the presence of either risk factor had 100% sensitivity, for ft attributable to N2 disease.
Conclusions: To reduce ft attributable to N2 disease, tissue biopsy for mediastinal staging should be considered for patients with pet-ct positive N1 status and with tumours larger than 3 cm even with a pet-ct negative mediastinum.
Keywords: Non-small-cell lung cancer; endobronchial ultrasonography; endoscopic ultrasonography; lymphatic metastasis or pathology; mediastinal staging; mediastinoscopy; positron-emission tomography–computed tomography; thoracotomy.
Similar articles
-
Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.Eur J Cardiothorac Surg. 2008 Jan;33(1):104-9. doi: 10.1016/j.ejcts.2007.09.026. Epub 2007 Oct 30. Eur J Cardiothorac Surg. 2008. PMID: 17977738
-
Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study.Chest. 2006 Dec;130(6):1791-5. doi: 10.1378/chest.130.6.1791. Chest. 2006. PMID: 17166998
-
Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.J Thorac Oncol. 2011 Aug;6(8):1367-72. doi: 10.1097/JTO.0b013e318220c912. J Thorac Oncol. 2011. PMID: 21587082 Clinical Trial.
-
Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.Eur J Cardiothorac Surg. 2009 Sep;36(3):440-5. doi: 10.1016/j.ejcts.2009.04.003. Epub 2009 May 22. Eur J Cardiothorac Surg. 2009. PMID: 19464906 Review.
-
ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer.Eur J Cardiothorac Surg. 2007 Jul;32(1):1-8. doi: 10.1016/j.ejcts.2007.01.075. Epub 2007 Apr 19. Eur J Cardiothorac Surg. 2007. PMID: 17448671
Cited by
-
Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer.Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):2084-97. doi: 10.1007/s00259-016-3407-4. Epub 2016 May 11. Eur J Nucl Med Mol Imaging. 2016. PMID: 27164899 Review.
-
Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer.Int J Clin Exp Med. 2015 Jun 15;8(6):9291-8. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26309587 Free PMC article.
-
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer.Clin Med Insights Oncol. 2023 Feb 14;17:11795549231152948. doi: 10.1177/11795549231152948. eCollection 2023. Clin Med Insights Oncol. 2023. PMID: 36818454 Free PMC article. Review.
-
Quality Gaps and Comparative Effectiveness in Lung Cancer Staging and Diagnosis.Chest. 2020 May;157(5):1322-1345. doi: 10.1016/j.chest.2019.09.025. Epub 2019 Oct 12. Chest. 2020. PMID: 31610159 Free PMC article.
-
Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?PLoS One. 2020 Apr 9;15(4):e0231258. doi: 10.1371/journal.pone.0231258. eCollection 2020. PLoS One. 2020. PMID: 32271810 Free PMC article.
References
-
- Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K, on behalf of the American College of Chest Physicians Treatment of non-small cell lung cancer stage i and stage ii: accp evidence-based clinical practice guidelines (2nd edition) Chest. 2007;132(suppl):234S–42S. doi: 10.1378/chest.07-1378. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous